卵巢卵黄囊瘤的管理与预后:美国国家癌症数据库分析
基于美国国家癌症数据库2004至2014年561例卵巢卵黄囊瘤患者的回顾性分析显示,多数为早期(I-II期,58.5%),I、II、III、IV期5年总生存率分别为94.8%、97.1%、70.9%、51.6%(P<0.001);青少年和年轻成人5年总生存率优于年长绝经前和绝经后女性(P<0.001);辅助化疗与更优总生存相关(P=0.016),早期、年轻及接受辅助化疗是独立预后因素。
要点
- 卵巢卵黄囊瘤患者多为早期(58.5%为I-II期),中位年龄23岁。
- I、II、III、IV期5年总生存率分别为94.8%、97.1%、70.9%、51.6%(P<0.001)。
- 辅助化疗与更优总生存相关(P=0.016),早期、年轻及辅助化疗为独立预后因素。
核心结论
- 卵巢卵黄囊瘤患者常表现为早期疾病,辅助化疗、早期分期和年轻年龄与更优结局相关。
研究设计与样本
- 查询美国国家癌症数据库,纳入2004年至2014年诊断为卵巢卵黄囊瘤的女性,共561例,中位年龄23岁。
- 采用Kaplan-Meier曲线计算总生存率,log-rank检验进行单因素分析,Cox模型确定独立死亡预测因素。
主要发现
- 58.5%为早期(I-II期),29.6%为III期,11.9%为IV期。
- I、II、III、IV期5年总生存率分别为94.8%、97.1%、70.9%、51.6%(P<0.001)。
- 青少年5年总生存率94.4%,年轻成人89.3%,年长绝经前女性67.6%,绝经后女性30.6%(P<0.001)。
- 接受辅助化疗者总生存优于未接受者(P=0.016)。
- 网膜切除术、子宫切除术和淋巴结取样/清扫术(LND)与更优总生存无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the clinico-pathological characteristics, management and prognosis of women diagnosed with ovarian yolk sac tumors (OYSTs). METHODS: The U.S National Cancer Data Base was queried for women diagnosed with OYST between 2004 and 2014. Overall survival (OS) was calculated following generation of Kaplan-Meir curves. Univariate analysis was performed with the log-rank test. A Cox model was constructed to determine independent predictors of mortality. RESULTS: A total of 561 women were identified with a median age of 23years. The majority (58.5%) had early stage (I-II), while 29.6% and 11.9% had stage III and IV disease respectively. Five-year OS for women with stage I, II, III and IV disease were 94.8%, 97.1%, 70.9% and 51.6% respectively, p<0.001. Better 5-yr OS was observed for adolescents (94.4%) and young adults (89.3%) compared to older premenopausal (67.6%) and postmenopausal women (30.6%), p<0.001. Omentectomy, hysterectomy and lymph node sampling/dissection (LND) were not associated with better OS. Women who received adjuvant chemotherapy had superior OS compared to those who did not, p=0.016. Early disease stage, younger age and receipt of adjuvant chemotherapy, but not LND were independently associated with better mortality. CONCLUSIONS: Women with OYST commonly present with early stage disease. Administration of adjuvant chemotherapy, early stage and younger age are associated with superior outcomes.
引用
- Nasioudis D, Chapman-Davis E, Frey MK, et al. Management and prognosis of ovarian yolk sac tumors; an analysis of the National Cancer Data Base. Gynecol Oncol. 2017. PMID: 28803748. doi:10.1016/j.ygyno.2017.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。